<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694405</url>
  </required_header>
  <id_info>
    <org_study_id>CT17_CIRN24_Achieve01</org_study_id>
    <nct_id>NCT03694405</nct_id>
  </id_info>
  <brief_title>Adolescent MenACWY Booster Study</brief_title>
  <official_title>A Randomized, Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada; a Canadian Immunization Research Network (CIRN) Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Center for Vaccinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Centre for Disease Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Immunization Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to confirm non-inferiority of the three MenACWY vaccines (Menveo, Menactra or&#xD;
      Nimenrix) in adolescents, and to identify whether the number of previous doses of MenC&#xD;
      influences the response to the MenACWY vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive one of the three doses of licensed MenACWY as a&#xD;
      booster dose in adolescents. Serology will be collect at 3 time points; prior to the booster&#xD;
      dose and 1 month and 1 year post-vaccination to measure antibody levels. The participants are&#xD;
      healthy students in grades 7-9 who have not received their MenACWY vaccine yet and received&#xD;
      their routine infant MenC vaccines per previous Canadian schedules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1 = 3 prior doses of MenC vaccine (Alberta), Group 2 = 2 prior doses of MenC vaccine (British Columbia), Group 3 = 1 prior dose of MenC vaccine (Nova Scotia). Group A = Menveo (MenACWY-CRM), Group B = Menactra (MenACWY-DT), Group C = Nimenrix (MenACWY-TT)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1-year post-MenACWY booster between groups with differing priming schedules</measure>
    <time_frame>1 year following MenACWY adolescent booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1-year post-MenACWY booster between differing vaccines</measure>
    <time_frame>1 year following MenACWY adolescent booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1 month post-MenACWY booster between groups with differing MenC priming schedules.</measure>
    <time_frame>1 month following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirm non-inferiority of MenC protection at 1 month post-MenACWY booster between groups with different MenACWY vaccines</measure>
    <time_frame>1 month following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis to determine effects of different MenACWY vaccines in subjects primed with different MenC schedules at 1 month and 1 year post-MenACWY booster</measure>
    <time_frame>1 month and 1 year following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis to determine effects of different MenC priming schedules in subjects receiving different MenACWY booster immunizations at 1 month and 1 year post-MenACWY booster</measure>
    <time_frame>1 month and 1 year following MenACWY booster</time_frame>
    <description>N. meningitidis capsular group C serum bactericidal antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirm safety of MenACWY conjugate vaccines</measure>
    <time_frame>Up to 1 month post-vaccine</time_frame>
    <description>Adverse events as reported by study participants</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Meningococcal Disease, Invasive</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>Booster vaccination with MenACWY-CRM</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 3A</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-DT</intervention_name>
    <description>Booster vaccination with MenACWY-DT</description>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_label>Group 3B</arm_group_label>
    <other_name>Menactra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-TT</intervention_name>
    <description>Booster vaccination with MenACWY-TT</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 3C</arm_group_label>
    <other_name>Nimenrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        All the following need to be fulfilled:&#xD;
&#xD;
          1. Healthy adolescent&#xD;
&#xD;
          2. Previous receipt of appropriate MenC vaccine according to the relevant provincial&#xD;
             schedule (see above)&#xD;
&#xD;
          3. Parent/legal guardian has given informed consent OR participant has given consent (if&#xD;
             participant demonstrates capacity to consent)&#xD;
&#xD;
          4. Participant has given consent (as above) OR assent.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        The participant may not enter the trial if ANY of the following apply:&#xD;
&#xD;
          1. Has already received any doses of MenACWY vaccine at any age&#xD;
&#xD;
          2. Previous confirmed or suspected meningococcal disease&#xD;
&#xD;
          3. Close contact with an individual with laboratory-confirmed N. meningitidis in prior 12&#xD;
             months&#xD;
&#xD;
          4. Previous allergic reaction to a component of any of the 3 vaccines&#xD;
&#xD;
          5. Serious chronic or progressive disease&#xD;
&#xD;
          6. Confirmed/suspected immunodeficiency&#xD;
&#xD;
          7. Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral&#xD;
             prednisolone &gt;0.5mL/kg/day or intravenous glucocorticoid steroid). Nasal, topical or&#xD;
             inhaled steroids are allowed&#xD;
&#xD;
          8. Administration of immunoglobulins within the prior 12 months and/or any blood products&#xD;
             planned during the study period&#xD;
&#xD;
          9. Pregnancy (based on history from adolescent and parent/legal guardian)&#xD;
&#xD;
         10. Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial.&#xD;
&#xD;
        TEMPORARY EXCLUSION CRITERIA If the adolescent has a temperature ≥ 38°C, then vaccination&#xD;
        (and blood sampling if due to occur at same visit) will be postponed until resolution of&#xD;
        fever.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Sadarangani, BM BCh DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Research Institute, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Center, BC Children's Hospital Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MenACWY</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

